Drug profile

The FDA adverse-event record for S-Adenosylmethionine/Silybin

16 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference S-Adenosylmethionine/Silybin. See the species affected, top reactions, and outcomes below.

16
adverse-event reports
12.5%
death-coded share
Dog
most-reported species
6
Other abnormal test result NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
2
Deaths Reported
12.5%
Death Rate

Active Ingredients

S-Adenosylmethionine/Silybin

Administration Routes

OralUnknown

Species Affected

Dog 14
Cat 2

Most Affected Breeds

Dachshund (unspecified) 2
Schnauzer - Miniature 2
Crossbred Canine/dog 1
Schnauzer (unspecified) 1
Retriever - Labrador 1
Terrier - West Highland White 1
Chihuahua 1
Maltese 1
Deutsche Dogge, Great Dane 1
Beagle 1

Most Reported Reactions

Other abnormal test result NOS 6
Elevated alanine aminotransferase (ALT) 3
Death by euthanasia 2
Lack of efficacy - NOS 2
Neoplasia NOS 2
Elevated serum alkaline phosphatase (SAP) 2
Acute renal failure 1
Not eating 1
Swelling NOS 1
Localised oedema (not application site) 1
Elevated creatinine 1
Elevated blood urea nitrogen (BUN) 1

Outcome Breakdown

Ongoing
6 (37.5%)
Outcome Unknown
4 (25.0%)
Recovered/Normal
3 (18.8%)
Euthanized
2 (12.5%)
Recovered with Sequela
1 (6.3%)

S-Adenosylmethionine/Silybin Adverse Event Insights

16 reports name S-Adenosylmethionine/Silybin; 2 recorded a death outcome (12.5% of reported events, not a population-level mortality rate). Active ingredient: S-Adenosylmethionine/Silybin. Administration routes: Oral, Unknown.

By species: Dog (14 reports), Cat (2 reports). By breed: Dachshund (unspecified) (2), Schnauzer - Miniature (2), Crossbred Canine/dog (1).

Leading clinical signs: Other abnormal test result NOS (6), Elevated alanine aminotransferase (ALT) (3), Death by euthanasia (2), Lack of efficacy - NOS (2). Outcome, 16 coded reports: Ongoing leads at 37.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.